Skip to main content
Home

Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE),  American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA). 

RSS icon

  • Video: Vivek Reddy, MD, Director, Cardiac Arrhythmia Service, The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology, Icahn School of Medicine at Mount Sinai, explains studies on the latest pulsed field ablation and leadless conduction pacing trials. #PFA #conductionpacing

    Exploring the latest data in PFA and leadless conduction system pacing

    Vivek Reddy, MD, spoke to Cardiovascular Business about some of the biggest trends in electrophysiology today.

  • Samuel Jones, MD, MPH, director of inpatient electrophysiology at the Memorial Hospital, Chattanooga Heart Institute, discusses concerns over new heart failure Medicare Ambulatory Specialty Model payment model that starts on Jan. 1, 2027.

    Cardiologists scramble to prepare for mandatory heart failure payment model

    Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 

  • President Trump's presidential proclamation Sept. 19 to implement a $100,000 fee for H-1B visa applications had immediate backlash from dozens of medical societies. Groups like the American Medical Association (AMA) and the American College of Cardiology (ACC) said this will cut off the flow of foreign physicians into the U.S. at a time when we cannot graduate enough American physicians to fill positions in a healthcare system that is facing a rapidly growing physician shortage.

    Trump administration exempts doctors from work visa freeze

    SCAI said reversing the processing hold allows physicians to continue serving patients and helps stabilize the workforce.

  • Devi Nair, MD, director of electrophysiology and research, St. Bernards Medical Center and Arrhythmia Research Group, spoke with Cardiovascular Business at the Heart Rhythm 2026 meeting in the above video interview. She explained both the explosion of PFA use since the first FDA approvals in 2024, and the recently discovered complications of coronary vessel spasm and hemolysis and how newer PFA technology might address this.

    PFA has been a game-changer for heart patients—but there are still risks

    Devi Nair, MD, reviewed some of the rare complications clinicians are seeing with PFA.

  • Cardiac amyloidosis on nuclear imaging of the heart using 11C-PiB PET/CT. Image courtesy of RSNA

    Cardiac amyloidosis in the spotlight at Heart Failure 2026

    Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy. 
 

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

prescription drugs

Cost-related medication non-adherence declined after the Inflation Reduction Act

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

robot reviewing heart data

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

 Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …2
    • Page 3
    • Page 4
    • Page 5
    • Current page 6
    • Page 7
    • Page 8
    • Page 9
    • Page 10 …
    • Next page Next ›
    • Last page Last »
Displaying 41 - 48 of 1526
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme